Dusa not one trick pony, $230M is fair offer, says Sun
This article was originally published in Scrip
Sun Pharmaceutical Industries $230 million acquisition of the dermatology firm, Dusa Pharmaceutical, brings with it significant limited competition potential in the US and other markets, though the Indian firm appears keen to buy more and buy bigger. Dusa is focused on developing and marketing its Levulan (aminolevulinic acid HCl) photodynamic therapy platform.
You may also be interested in...
New rules in India specify that a marketer of a drug will share the onus for quality and compliance along with the manufacturer. Enhanced punishment for misleading advertisements for a range of illnesses is also proposed, while calls for a statute to regulate pharma's marketing practices grow louder.
Former managing director of Janssen India to helm Bharat Serums and Vaccines following the firm’s acquisition by private equity firm Advent International.
Deal news from Strides Pharma, Pharmaceutics Intl., Cipla, Wanbury, AstraZeneca, Syntekabio, Arctoris, Mundipharma, Samsung Bioepis…